Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005835 · ClinicalTrials.gov registry record · Phase 1
N99-02: Melphalan and Buthionine Sulfoximine
A Phase 1 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 9
- Study locations
NCT00005835: Completed Phase 1 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
NCT00005835 is a Phase 1 study of Neuroblastoma that has completed, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 31 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005835, a Phase 1 study of Neuroblastoma, has completed, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of melphalan and buthionine sulfoximine followed by bone marrow or peripheral stem cell transplantation in treating children who have resistant or recurrent neuroblastoma.
Conditions Studied
Interventions
- DRUG melphalan
- DRUG buthionine sulfoximine
- PROCEDURE Peripheral blood stem cell infusion
- OTHER Filgrastim
Study Locations (9)
California
- Childrens Hospital Los Angeles - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago Comer Children's Hospital - Chicago
Massachusetts
- Childrens Hospital Boston, Dana-Farber Cancer Institute. - Boston
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Cook Children's Medical Center - Fort Worth - Fort Worth
Washington
- Children's Hospital and Regional Medical Center - Seattle - Seattle
Ontario
- Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2001-08 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT00005835 record still lists
NCT00005835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 4 interventions - of which melphalan is the first listed.
NCT00005835 lists 9 locations in 8 states (California, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00005835 about?
NCT00005835 is a clinical study titled "N99-02: Melphalan and Buthionine Sulfoximine". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE:...
What is the current status of trial NCT00005835?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2001-08. Estimated completion is 2016-04.
What conditions does trial NCT00005835 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT00005835?
The interventions under investigation include: melphalan (DRUG), buthionine sulfoximine (DRUG), Peripheral blood stem cell infusion (PROCEDURE), Filgrastim (OTHER).
Who is sponsoring clinical trial NCT00005835?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005835 being conducted?
This trial has 9 study locations across California, Illinois, Massachusetts, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005835's enrollment target sits among peer trials
31 59th of 94 higher than 36 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia